Drugs group Shire gains management commitment to corporate venturing.
London and Nasdaq-listed drugs company Shire has committed to starting a corporate venturing activity and has agreed its first, as yet undisclosed investment.
Gwen Melincoff, senior vice-president of business development at Shire, by email said: "With regard to Shire’s corporate venturing – while still a work in progress, there is management commitment to doing this."
She added the first corporate venturing deal had been completed just before Christmas.
Shire has developed through organic growth on attention deficit hyperactivity disorder,…
